The global Nanopharmaceuticals market size was valued at US$ 40600 million in 2024 and is forecast to a readjusted size of USD 92900 million by 2031 with a CAGR of 12.7% during review period.
Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their 鈥渂ulk鈥� counterparts primarily because of size.
There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
This report is a detailed and comprehensive analysis for global Nanopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Nanopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K MT), and ASP (USD/MT), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Nanopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Nanopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Nanopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Liposomes
Polymeric Micelles
Solid Lipid Nanoparticles
Microemulsion and Nnanoemulsion
Nanosuspension
麻豆原创 segment by Application
Cancer and Tumor
Autoimmune Disorders
Inflammation
Others
Major players covered
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nanopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nanopharmaceuticals, with price, sales quantity, revenue, and global market share of Nanopharmaceuticals from 2020 to 2025.
Chapter 3, the Nanopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nanopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Nanopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nanopharmaceuticals.
Chapter 14 and 15, to describe Nanopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Nanopharmaceuticals Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Liposomes
1.3.3 Polymeric Micelles
1.3.4 Solid Lipid Nanoparticles
1.3.5 Microemulsion and Nnanoemulsion
1.3.6 Nanosuspension
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Nanopharmaceuticals Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Cancer and Tumor
1.4.3 Autoimmune Disorders
1.4.4 Inflammation
1.4.5 Others
1.5 Global Nanopharmaceuticals 麻豆原创 Size & Forecast
1.5.1 Global Nanopharmaceuticals Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Nanopharmaceuticals Sales Quantity (2020-2031)
1.5.3 Global Nanopharmaceuticals Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Nanopharmaceuticals Product and Services
2.1.4 Merck Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Nanopharmaceuticals Product and Services
2.2.4 Pfizer Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Pfizer Recent Developments/Updates
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Nanopharmaceuticals Product and Services
2.3.4 Novartis Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Novartis Recent Developments/Updates
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Nanopharmaceuticals Product and Services
2.4.4 Abbott Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Abbott Recent Developments/Updates
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Nanopharmaceuticals Product and Services
2.5.4 GlaxoSmithKline Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 GlaxoSmithKline Recent Developments/Updates
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Nanopharmaceuticals Product and Services
2.6.4 Roche Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Roche Recent Developments/Updates
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Nanopharmaceuticals Product and Services
2.7.4 Sanofi Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Sanofi Recent Developments/Updates
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Nanopharmaceuticals Product and Services
2.8.4 Eli Lilly Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Eli Lilly Recent Developments/Updates
2.9 Astrazeneca
2.9.1 Astrazeneca Details
2.9.2 Astrazeneca Major Business
2.9.3 Astrazeneca Nanopharmaceuticals Product and Services
2.9.4 Astrazeneca Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Astrazeneca Recent Developments/Updates
2.10 Johnson & Johnson
2.10.1 Johnson & Johnson Details
2.10.2 Johnson & Johnson Major Business
2.10.3 Johnson & Johnson Nanopharmaceuticals Product and Services
2.10.4 Johnson & Johnson Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Johnson & Johnson Recent Developments/Updates
2.11 Celgene
2.11.1 Celgene Details
2.11.2 Celgene Major Business
2.11.3 Celgene Nanopharmaceuticals Product and Services
2.11.4 Celgene Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Celgene Recent Developments/Updates
2.12 Novavax
2.12.1 Novavax Details
2.12.2 Novavax Major Business
2.12.3 Novavax Nanopharmaceuticals Product and Services
2.12.4 Novavax Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Novavax Recent Developments/Updates
2.13 Stryker
2.13.1 Stryker Details
2.13.2 Stryker Major Business
2.13.3 Stryker Nanopharmaceuticals Product and Services
2.13.4 Stryker Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Stryker Recent Developments/Updates
2.14 Gilead Sciences
2.14.1 Gilead Sciences Details
2.14.2 Gilead Sciences Major Business
2.14.3 Gilead Sciences Nanopharmaceuticals Product and Services
2.14.4 Gilead Sciences Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Gilead Sciences Recent Developments/Updates
2.15 OSI Pharmaceuticals
2.15.1 OSI Pharmaceuticals Details
2.15.2 OSI Pharmaceuticals Major Business
2.15.3 OSI Pharmaceuticals Nanopharmaceuticals Product and Services
2.15.4 OSI Pharmaceuticals Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 OSI Pharmaceuticals Recent Developments/Updates
2.16 Kadmon Pharmaceuticals
2.16.1 Kadmon Pharmaceuticals Details
2.16.2 Kadmon Pharmaceuticals Major Business
2.16.3 Kadmon Pharmaceuticals Nanopharmaceuticals Product and Services
2.16.4 Kadmon Pharmaceuticals Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Kadmon Pharmaceuticals Recent Developments/Updates
2.17 Samyang Biopharm
2.17.1 Samyang Biopharm Details
2.17.2 Samyang Biopharm Major Business
2.17.3 Samyang Biopharm Nanopharmaceuticals Product and Services
2.17.4 Samyang Biopharm Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Samyang Biopharm Recent Developments/Updates
2.18 Mitsubishi Pharma
2.18.1 Mitsubishi Pharma Details
2.18.2 Mitsubishi Pharma Major Business
2.18.3 Mitsubishi Pharma Nanopharmaceuticals Product and Services
2.18.4 Mitsubishi Pharma Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Mitsubishi Pharma Recent Developments/Updates
2.19 Kaken Pharmaceutical
2.19.1 Kaken Pharmaceutical Details
2.19.2 Kaken Pharmaceutical Major Business
2.19.3 Kaken Pharmaceutical Nanopharmaceuticals Product and Services
2.19.4 Kaken Pharmaceutical Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 Kaken Pharmaceutical Recent Developments/Updates
2.20 Selecta Biosciences
2.20.1 Selecta Biosciences Details
2.20.2 Selecta Biosciences Major Business
2.20.3 Selecta Biosciences Nanopharmaceuticals Product and Services
2.20.4 Selecta Biosciences Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Selecta Biosciences Recent Developments/Updates
2.21 Par Pharmaceutical
2.21.1 Par Pharmaceutical Details
2.21.2 Par Pharmaceutical Major Business
2.21.3 Par Pharmaceutical Nanopharmaceuticals Product and Services
2.21.4 Par Pharmaceutical Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 Par Pharmaceutical Recent Developments/Updates
2.22 Cerulean Pharma
2.22.1 Cerulean Pharma Details
2.22.2 Cerulean Pharma Major Business
2.22.3 Cerulean Pharma Nanopharmaceuticals Product and Services
2.22.4 Cerulean Pharma Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.22.5 Cerulean Pharma Recent Developments/Updates
2.23 Navidea Biopharmaceuticals
2.23.1 Navidea Biopharmaceuticals Details
2.23.2 Navidea Biopharmaceuticals Major Business
2.23.3 Navidea Biopharmaceuticals Nanopharmaceuticals Product and Services
2.23.4 Navidea Biopharmaceuticals Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.23.5 Navidea Biopharmaceuticals Recent Developments/Updates
2.24 Lummy
2.24.1 Lummy Details
2.24.2 Lummy Major Business
2.24.3 Lummy Nanopharmaceuticals Product and Services
2.24.4 Lummy Nanopharmaceuticals Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.24.5 Lummy Recent Developments/Updates
3 Competitive Environment: Nanopharmaceuticals by Manufacturer
3.1 Global Nanopharmaceuticals Sales Quantity by Manufacturer (2020-2025)
3.2 Global Nanopharmaceuticals Revenue by Manufacturer (2020-2025)
3.3 Global Nanopharmaceuticals Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Nanopharmaceuticals by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Nanopharmaceuticals Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Nanopharmaceuticals Manufacturer 麻豆原创 Share in 2024
3.5 Nanopharmaceuticals 麻豆原创: Overall Company Footprint Analysis
3.5.1 Nanopharmaceuticals 麻豆原创: Region Footprint
3.5.2 Nanopharmaceuticals 麻豆原创: Company Product Type Footprint
3.5.3 Nanopharmaceuticals 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Nanopharmaceuticals 麻豆原创 Size by Region
4.1.1 Global Nanopharmaceuticals Sales Quantity by Region (2020-2031)
4.1.2 Global Nanopharmaceuticals Consumption Value by Region (2020-2031)
4.1.3 Global Nanopharmaceuticals Average Price by Region (2020-2031)
4.2 North America Nanopharmaceuticals Consumption Value (2020-2031)
4.3 Europe Nanopharmaceuticals Consumption Value (2020-2031)
4.4 Asia-Pacific Nanopharmaceuticals Consumption Value (2020-2031)
4.5 South America Nanopharmaceuticals Consumption Value (2020-2031)
4.6 Middle East & Africa Nanopharmaceuticals Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Nanopharmaceuticals Sales Quantity by Type (2020-2031)
5.2 Global Nanopharmaceuticals Consumption Value by Type (2020-2031)
5.3 Global Nanopharmaceuticals Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Nanopharmaceuticals Sales Quantity by Application (2020-2031)
6.2 Global Nanopharmaceuticals Consumption Value by Application (2020-2031)
6.3 Global Nanopharmaceuticals Average Price by Application (2020-2031)
7 North America
7.1 North America Nanopharmaceuticals Sales Quantity by Type (2020-2031)
7.2 North America Nanopharmaceuticals Sales Quantity by Application (2020-2031)
7.3 North America Nanopharmaceuticals 麻豆原创 Size by Country
7.3.1 North America Nanopharmaceuticals Sales Quantity by Country (2020-2031)
7.3.2 North America Nanopharmaceuticals Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Nanopharmaceuticals Sales Quantity by Type (2020-2031)
8.2 Europe Nanopharmaceuticals Sales Quantity by Application (2020-2031)
8.3 Europe Nanopharmaceuticals 麻豆原创 Size by Country
8.3.1 Europe Nanopharmaceuticals Sales Quantity by Country (2020-2031)
8.3.2 Europe Nanopharmaceuticals Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Nanopharmaceuticals Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Nanopharmaceuticals Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Nanopharmaceuticals 麻豆原创 Size by Region
9.3.1 Asia-Pacific Nanopharmaceuticals Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Nanopharmaceuticals Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Nanopharmaceuticals Sales Quantity by Type (2020-2031)
10.2 South America Nanopharmaceuticals Sales Quantity by Application (2020-2031)
10.3 South America Nanopharmaceuticals 麻豆原创 Size by Country
10.3.1 South America Nanopharmaceuticals Sales Quantity by Country (2020-2031)
10.3.2 South America Nanopharmaceuticals Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Nanopharmaceuticals Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Nanopharmaceuticals Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Nanopharmaceuticals 麻豆原创 Size by Country
11.3.1 Middle East & Africa Nanopharmaceuticals Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Nanopharmaceuticals Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Nanopharmaceuticals 麻豆原创 Drivers
12.2 Nanopharmaceuticals 麻豆原创 Restraints
12.3 Nanopharmaceuticals Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Nanopharmaceuticals and Key Manufacturers
13.2 Manufacturing Costs Percentage of Nanopharmaceuticals
13.3 Nanopharmaceuticals Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Nanopharmaceuticals Typical Distributors
14.3 Nanopharmaceuticals Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
听
听
*If Applicable.
